glp-1 ulcerative colitis The alleviating effect and mechanism of GLP-1 on ulcerative colitis

Role of glucagon-like peptides in inflammatory bowel diseases—current knowledge and future perspectives | Naunyn-Schmiedeberg's Archives of Pharmacology

23.97

★★★★☆4.8 (126)

New research published in the Foundation's journal Crohn's & Colitis 360 found that people with IBD who use GLP-1 medications—commonly prescribed for diabetes and obesity—had a lower risk of major heart-related complications

21.59

★★★★★4.9 (98)

GLP-1R agonists modulate ulcerative colitis risk. New research alert! Using #Multiomics MR, colocalization, #Epigenomics, #RNAseq, and #scRNAseq analyses, this study demonstrates that GLP-1R agonists modulate ulcerative colitis risk by driving specific

21.72

★★★★★5.0 (157)

Protective effect of Dulaglutide, a GLP1 agonist, on acetic acid-induced ulcerative colitis in rats: involvement of GLP-1, TFF-3, and TGF-β/PI3K/NF-κB signaling pathway | Naunyn-Schmiedeberg's Archives of Pharmacology

22.71

★★★★★4.7 (84)

Primer: The Skinny on GLP-1s

20.88

★★★★★4.9 (203)

GLP-1RAs for IBD

22.48

★★★★★5.0 (176)

Ulcerative colitis and GLP-1 medications are a major focus for scientists right now. Here's what's happening: between 2024 and 2025, at least six studies have been published in respected journals like Oxford

29.95

★★★★★4.8 (132)